Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026.

https://investors.tenayatherapeutics.com/news-releases/news-release-details/tenaya-therapeutics-appoints-eric-hyllengren-chief-financial/